Effect of formoterol with or without budesonide in repeated low-dose allergen challenge

European Respiratory Journal

Volumn 33, Issue 4, 2009, Pages 747-753

  Dahlen B ^a,b   Lantz, A S ^a,b   Ihre, E ^c   Skedinger, M ^a,b   Henriksson, E ^a,b   Jorgensen L ^d   Ekstrom T ^d   Dahlen S E ^b   Larsson, K ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Cityakuten   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Airway hyperresponsiveness; Allergic asthma; Bronchoprovocation; Exhaled nitric oxide; Inhaled corticosteroids; Long acting agonists

Indexed keywords

ALLERGEN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; FORMOTEROL; METHACHOLINE; NITRIC OXIDE; PLACEBO; PROSTAGLANDIN D2;

ADULT; ALLERGIC ASTHMA; ARTICLE; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DETERIORATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENVIRONMENTAL EXPOSURE; EOSINOPHIL; EVENING DOSAGE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY TRACT INFLAMMATION; SPUTUM ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; ANALYSIS OF VARIANCE; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHODILATOR AGENTS; BUDESONIDE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; SPUTUM; TREATMENT OUTCOME;

EID: 63849253202     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00095508     Document Type: Article

References (24)

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention: NHLBI/WHO workshop report. Bethesda, National Heart Lung and Blood Institute, 2006. Available from www.ginasthma.org.
2. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720-1745.
3. 2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285: 2583-2593.
4. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group, The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26.
5. Pauwels RA, Sears MR, Campbell M, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003; 22: 787-794.
6. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219-224.
7. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488.
8. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-1411.
9. O'Byrne P, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392-1397.
10. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-136.
11. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368: 744-753.
12. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007; 356: 2040-2052.
13. Haahtela T, Tamminen K, Malmberg LP, et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study. Eur Respir J 2006; 28: 748-755.
14. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993; 147: 697-704.
15. Jeffery PK, Godfrey RW, Adelroth E, Nelson F, Rogers A, Johansson SA. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 1992; 145: 890-899.
16. Ihre E, Zetterström O. Increase in non-specific bronchial responsiveness after repeated inhalation of low doses of allergen. Clin Exp Allergy 1993; 23: 298-305.
17. Ihre E, Gyllfors P, Gustafsson LE, Kumlin M, DahlenB. Early rise in exhaled nitric oxide and mast cell activation in repeated low-dose allergen challenge. Eur Respir J 2006; 27: 1152-1159.
18. Gauvreau GM, Sulakvelidze I, Watson RM, Inman MD, Rerecich TJ, O'Byrne PM. Effects of once daily dosing with inhaled budesonide on airway hyperresponsiveness and airway inflammation following repeated low-dose allergen challenge in atopic asthmatics. Clin Exp Allergy 2000; 30: 1235-1243.
19. Roquet A, Dahlén B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155: 1856-1863.
20. Recommendations for standardized procedures for the online and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 1999; 160: 2104-2117.
21. Standardization of Spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
22. de Kluijver J, Evertse CE, Schrumpf JA, et al. Asymptomatic worsening of airway inflammation during low-dose allergen exposure in asthma: protection by inhaled steroids. Am J Respir Crit Care Med 2002; 166: 294-300.
23. Kraft M, Israel E, O'Connor GT. Clinical Decisions. Treatment of mild persistent asthma. N Engl J Med 2007; 356: 2096-2100.
24. American Lung Association Asthma Clinical Research Centers, Peters SP, Anthonisen N, et al. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007; 356: 2027-2039.